Procter & Gamble Health Q1 FY27 profit jumps 45%

Key takeaway from the June-quarter update

Procter & Gamble Health Ltd. reported a sharp rise in standalone profit for the first quarter of FY27, aided by a one-time gain from the sale of an office property in Mumbai. The company posted a standalone net profit of ₹96.15 crore for the quarter ended June 30, 2026, up 45% from ₹66.18 crore in the same quarter last year. Revenue growth, meanwhile, was steady rather than dramatic, indicating that the jump in headline profit was not purely driven by operating performance. The results were approved by the Board of Directors on August 6, 2026, after review by the Audit Committee. The company also disclosed that statutory auditors Haribhakti & Co. LLP carried out a limited review and issued an unmodified conclusion.

Procter & Gamble Health: headline Q1 FY27 numbers

For Q1 FY27, Procter & Gamble Health’s revenue from operations stood at ₹363.71 crore, a 7.37% increase from ₹338.74 crore in Q1 FY26. Total income for the quarter rose to ₹367.59 crore from ₹342.77 crore a year earlier. Total expenses increased to ₹270.27 crore from ₹253.96 crore year-on-year. Earnings per share (basic and diluted, after exceptional items) were reported at ₹57.92, up from ₹39.87 in the year-ago quarter. The company’s numbers indicate a quarter where the top line moved up at a mid-single digit pace, while the bottom line benefited from a non-recurring item.

Exceptional item: Worli office premises sale

A key driver of the quarter’s profit growth was an exceptional gain from the sale of an office premises property in Worli. The company reported an exceptional gain of ₹31.80 crore on this transaction. The property was sold for ₹33.34 crore against a carrying amount of ₹1.54 crore. This exceptional gain helped lift reported net profit for the quarter.

The disclosure is significant because it changes how investors interpret the quarter’s profitability. With a large one-time gain in the income statement, the headline profit number captures both the underlying business performance and the impact of the asset sale. This is why separating “before exceptional items” and “including exceptional items” becomes important when assessing the quarter.

Profit before exceptional items shows a different picture

Alongside the statutory financials, the provided data also includes a split of profitability that highlights the effect of the exceptional item. Net profit before exceptional items was reported at ₹64.35 crore in Q1 FY27 versus ₹66.18 crore in Q1 FY26, a decline of 2.8% year-on-year. Net profit including exceptional items rose to ₹96.15 crore from ₹66.18 crore, up 45.3%.

The numbers suggest that while revenue rose, profit growth at the headline level was largely driven by the exceptional gain rather than a step change in underlying profitability. This distinction matters for readers tracking earnings quality and the repeatability of earnings.

Operating performance and costs in the quarter

Operating metrics included in the data show EBITDA at ₹99.60 crore in Q1 FY27 compared with ₹90.30 crore in Q1 FY26, a 10.3% increase. At the same time, total expenses moved up to ₹270.27 crore from ₹253.96 crore, consistent with a year-on-year rise in the cost base.

While EBITDA growth indicates some improvement at the operating level, the decline in net profit before exceptional items highlights that other factors below EBITDA also influenced the quarter’s bottom line. The company’s disclosures in the provided text do not include segment-level commentary beyond referencing steady organic growth in its pharmaceutical segment.

Financial reporting, approvals, and audit status

Procter & Gamble Health said the unaudited financial results for the quarter ended June 30, 2026 were reviewed by the Audit Committee and approved by the Board of Directors on August 6, 2026. The company stated the financial results are in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Haribhakti & Co. LLP, the statutory auditors, conducted a limited review of the financial statements. The auditors concluded that nothing came to their attention that would cause them to believe the statement contained any material misstatement. The additional audit-related detail in the text also notes the review was conducted in line with SRE 2410 and that the statements were prepared in accordance with Ind AS 34.

Quick details and dividend-related disclosure in the data

The provided information also includes quick data points for Procter & Gamble Health, including a results date of August 06, 2026, and references to the prior quarter’s revenue of ₹370.45 crore and prior quarter PAT of ₹94.60 crore. It also lists a market cap of ₹10,963.06 crore and a CMP of ₹6,604.5.

Separately, the text states a board meeting is scheduled for August 06, 2026 to consider audited financial results and recommend dividend for FY2026, and that the board has recommended a final dividend of ₹45 per share, subject to shareholder approval at the 59th AGM and payable on or before September 25, 2026. These items are presented as part of the same collection of details provided.

Key metrics table: Procter & Gamble Health (standalone)

Not to confuse: Procter & Gamble Hygiene and Health Care (PGHH) Q1 FY27

The provided text also contains a separate set of results for Procter & Gamble Hygiene and Health Care Limited (NSE: PGHH), a different listed entity. For PGHH, the Board approved unaudited financial results for the quarter ended June 30, 2026 at a meeting held on July 29, 2026. PGHH reported net profit of ₹126.27 crore in Q1 FY27, representing a year-on-year decline of about 34% from ₹192.06 crore in Q1 FY26. Revenue from operations was ₹891.46 crore, down 4.9% year-on-year from ₹937.03 crore.

The data for PGHH also cites operating EBITDA of ₹170.06 crore versus ₹266.17 crore a year earlier and an EBITDA margin of 19.08% versus 28.41%. Basic and diluted EPS was ₹38.90 in Q1 FY27, down from ₹59.17 in Q1 FY26. PGHH’s statutory auditors, Kalyaniwalla & Mistry LLP, carried out a limited review under SRE 2410 and issued a review report stating nothing came to their attention suggesting a material misstatement. The text also notes finance costs rose to ₹3.11 crore from ₹0.27 crore year-on-year.

What investors typically track from here

For Procter & Gamble Health, the key follow-through item in the disclosures is the distinction between profit including and excluding exceptional items, given the meaningful contribution from the Worli asset sale. The next set of updates investors usually look for in such cases include any further disclosures on the use of proceeds, if made, and whether operating profitability (as reflected in measures such as EBITDA and profit before exceptional items) improves without reliance on one-off gains.

For PGHH, the data points highlight pressure on revenue and profitability in Q1 FY27, including lower revenue from operations and a sharp contraction in EBITDA and margins. The company’s disclosure in the provided text also notes it did not disclose category-wise sales, volume trends, or guidance for the remainder of FY27.

Conclusion

Procter & Gamble Health’s Q1 FY27 results show a 45% rise in reported profit, supported by a ₹31.80 crore exceptional gain from a Worli property sale, while revenue from operations increased 7.4% year-on-year. The results were approved on August 6, 2026 and subjected to a limited review with an unmodified conclusion. The provided details also reference a final dividend recommendation of ₹45 per share, subject to shareholder approval at the 59th AGM, with payment on or before September 25, 2026.